Decoy Therapeutics announces that Massachusetts Institute of Technology, MIT, Professor and Moderna co-founder Robert Langer, ScD will join the company’s Scientific Advisory Board, SAB, upon the successful completion of Decoy’s merger with Salarius Pharmaceuticals (SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with the newly formed company to be named Decoy Therapeutics.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRX: